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Influenza is a vaccine preventable disease that causes severe illness and excess mortality in humans. Licensed influenza vaccines
induce humoral immunity and protect against strains that antigenically match the major antigenic components of the vaccine, but
much less against antigenically diverse influenza strains. A vaccine that protects against diﬀerent influenza viruses belonging to the
same subtype or even against viruses belonging to more than one subtype would be a major advance in our battle against influenza.
Heterosubtypic immunity could be obtained by cytotoxic T-cell (CTL) responses against conserved influenza virus epitopes. The
molecular mechanisms involved in inducing protective CTL responses are discussed here. We also focus on CTL vaccine design and
point to the importance of immune-related databases and immunoinformatics tools in the quest for new vaccine candidates. Some
techniques for analysis of T-cell responses are also highlighted, as they allow estimation of cellular immune responses induced by
vaccine preparations and can provide correlates of protection.
1. Introduction
Influenza is responsible for three to five million cases
of severe illness and about 250 000 to 500 000 deaths
each year worldwide (http://www.who.int/mediacentre/fact-
sheets/fs211/en/index.html). These numbers, together with
increased disease awareness and focus on pandemic pre-
paredness, have contributed to the important growth of the
market for influenza vaccines over the last years [1].
Current vaccines for seasonal and pandemic influenza
come as inactivated whole virus, split virus, subunit vaccines,
or live attenuated viruses [2]. They are produced starting
from viruses grown on embryonated chicken eggs or in
mammalian cell culture and some of them are combined
with adjuvants. These conventional vaccines mainly aim
to induce a strong humoral immune response directed
against the hemagglutinin (HA) and the neuraminidase
(NA) glycoproteins, the main antigenic determinants on the
surface of influenza A and B virions. But the continuous
accumulation of mutations in hot-spots of HA and NA
that result in altered antigenic properties of these antigens
dictates the need for annual updates of human influenza
vaccines. As a result of this process, called antigenic drift,
these vaccines induce eﬀective protection only when the virus
seed strains used for vaccine production antigenically match
the circulating strains.
The process of antigenic drift could be driven by the
selection of viruses with increased receptor binding avidity
that emerge in vivo under the selective pressure of virus
neutralizing antibodies [3].
Antigenic drift makes development and production of
influenza vaccines challenging because the strains used for
producing the vaccine for the coming season have to be
selected by making predictions based on a worldwide survey
of circulating strains by the World Health Organization
Global Influenza Surveillance Network. Moreover, the sea-
sonal vaccines should be available in the pharmacies shortly
before or at the beginning of the next influenza season,
but it is often diﬃcult to predict when that will occur.
Moreover, prediction of the next emerging pandemic strain
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is impossible. Collectively, these uncertainties impose risks
for society and put extra pressure on vaccine producers. A
vaccine that elicits protection against several clades within
the same subtype or even induces heterosubtypic immunity
(HSI), that is, protects against multiple influenza subtypes,
would reduce this time pressure and allow more time
for eﬀective immunization. Such broadly reactive vaccines
would also protect against newly emerging influenza sub-
types that have epidemic or pandemic potential. The protec-
tive scope of seasonal protein vaccines can be broadened to
some extent by administering them with adjuvants such as
squalene-based MF59 (Novartis [4]) or AS03 (GlaxoSmithK-
line [5]), which have been licensed for human use. Some
experimental adjuvants, such as ISCOMs (an immunostimu-
lating complex already tested in humans [6, 7]), and possibly
also live attenuated vaccines, can induce substantial cellular
immunity. The cellular arm of the immune system can
provide HSI by inducing cytotoxic T cell (CTL) immunity
directed against conserved influenza virus antigens [8, 9] and
combining conserved immunogenic protein sequences from
diﬀerent influenza virus strains might result in a vaccine
that protects against most current and future circulating
influenza strains [10]. Another strategy for the induction
of HSI shown to be eﬀective in mouse models is based
on raising immunity against the conserved proteins of the
influenza virus. These include the matrix protein1 (M1)
and matrix protein 2 (M2) or even only its ectodomain
(M2e) [11–15], the internal nucleoprotein (NP) [16, 17], the
nonstructural protein (NS1), and the polymerases (PA, PB1,
PB2) [18].
Several of the new approaches aiming at the induc-
tion of HSI by targeting conserved influenza virus anti-
gens are now in clinical trials, but none of them has
made it to the market yet (http://clinicaltrials.gov/). For
example, an M2e-based vaccine, developed in our lab-
oratory [19], has successfully passed a phase I clini-
cal study http://www.acambis.com/default.asp-id=2039.htm.
The mechanism by which the M2e-based protein vaccine
protects against a homologous or heterologous challenge in
mice presumably relies on antibody-dependent cytotoxicity.
In contrast, vaccines directed against the conserved internal
influenza proteins are based mainly on the activation of
cytotoxic CD8+ T cells. Less well understood are the
contributions of CD4+ T cells to HSI during influenza
infections. Besides their classical helper role, CD4+ T cells
also exert a cytolytic eﬀect on influenza-infected cells in
mice [20]. In this review, we summarize the mechanisms
that are essential to prime CTLs, how CTL-inducing vaccines
should be designed, and how influenza virus-specific CTLs
counteract influenza infection. In addition, we focus on the
use of bioinformatics and easily accessible and searchable
epitope databases to build better and novel CTL-based
influenza vaccines. Finally, the analysis of vaccine eﬃcacy
and measurement of correlates of protection for CTL based
vaccines against influenza is addressed. The technology to
demonstrate and quantify pathogen-specific, functional CTL
responses is now available in most immunology research
laboratories but is still too complex for implementation in
routine clinical biology laboratories.
2. Mechanism of CTL Priming
Before going into the challenges of developing successful
CTL-dependent vaccines for influenza, we will briefly sum-
marize the molecular mechanisms and cellular interactions
required for induction of antigen-specific CTLs. The process
of priming antigen-specific CTL is initiated when the T-
cell receptor (TCR) of a naive CD8+ T cell binds a peptide
presented by a major histocompatibility type I molecular
complex (MHC-I) on an antigen presenting cell (APC).
However, peptide recognition by the TCR alone is not
suﬃcient to initiate a potent CTL response; activation of the
CD8+ cell also requires a costimulatory signal provided by
the binding of CD28 on the CTL to its ligand B7 on the
APC [21]. Nevertheless, sometimes naive CD8+ T cells are
not activated by interaction with APCs alone, and in such
cases the bystander help of CD4+ T cells recognizing a related
antigen on the same APC is required.
For an antigen to be presented properly on MHC-
I complexes, it typically has to be produced de novo in
the cytosol. The endogenous protein is then degraded by
the proteasome or other cellular proteases into peptides,
which are transported to the endoplasmic reticulum (ER)
by the transporter associated with antigen processing (TAP).
Once in the ER, the peptides are loaded on the MHC-I
molecules with the help of tapasin, and the stable MHC-I-
peptide complexes are transported to the cell surface of the
APC. Of the licensed influenza vaccines mentioned above,
only live-attenuated fulfill the requirements for de novo
vaccine antigen production in the APC or the influenza
virus-infected cell. The intracellular production of antigen
during viral replication after administration of the cold-
adapted vaccine licensed in North-America [22] and Russia
could, in principle, induce CTL-based immunity. Indeed,
the induction of long-living and protective CTL-dependent
HSI by live attenuated influenza viruses has been observed
in mouse models [23]. However, it is unclear if such CTL-
based HSI is also induced in humans and, if so, broadens
the clinical protection aﬀorded by live-attenuated compared
to inactivated influenza vaccines. Noteworthy, however, is
that exogenous antigens can also be presented on MHC-
I molecules by specialized APCs such as dendritic cells
(DCs) by a process called cross-priming (reviewed in [24]).
The priming of CTL responses by whole inactivated virus
vaccines against influenza probably occurs after such cross-
presentation [25].
MHC-I molecules in humans are also called human
leukocyte antigens (HLAs). These HLAs show a high degree
of polymorphism, making it possible that every individual
has her/his personalized HLA. This HLA restriction imposes
a severe constraint on the development of CTL-based
vaccines because, from the same protein, diﬀerent HLA-
matching peptide epitopes are presented, and ideally all
peptide antigens should be represented in the vaccine. What
has been very helpful for vaccine design was the grouping of
most HLA molecules into nine supertypes based on peptide
binding specificities [26]. Therefore, if one wants to design a
CTL-based vaccine that covers over 90% of the population,
multiple or promiscuous epitopes that match most of the
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HLA supertypes have to be included. The situation is much
simpler for experimental CTL vaccines that are evaluated
in inbred mouse strains, as only one or few haplotypes are
relevant for the population under investigation. In the quest
for new epitopes (see also below), one should also consider
the rank of an epitope in the immunodominance hierar-
chy respected by the host’s immune system. A dominant
epitope within a pool of foreign epitopes will by definition
draw most of the immunological attention, resulting in
a poor immune response to subdominant epitopes. This
dominance, however, is not always fixed, because a second
encounter with influenza (e.g., a later infection) may alter
dominance hierarchies. The immunodominance hierarchy
of CD8+ T-cells is dependent also on antigen dose and
on T-cell precursor frequencies resulting from the previous
infection [27]. The same principles of immunodominance
might apply to vaccination. A subdominant epitope can
gain an immunological lead over a dominant one because
only the former was included in a vaccine or due to
mutation of the dominant epitope. This will cause the
relative immunodominance to change upon challenge [28,
29] because T-cell precursors specific for the subdominant
epitope, raised by the prophylactic vaccine, are already
present at the time of challenge. Therefore, it is important
to have an idea about the immunohierarchy of diﬀerent
epitopes combined in one vaccine or present in diﬀerent
vaccines that are given together, and to make an adequate
estimation of the preexisting pool of primed T cells already
present in the host to be vaccinated.
3. Protection by CTL Vaccines
Once CTLs are primed by vaccination, they can recognize
infected cells that present viral peptides on their MHC-I
molecules. This implies that in a vaccinated individual at
least one round of infection is needed for CTLs to exert
their antiviral activity. Vaccine-primed CTLs can protect
mice against a lethal influenza challenge [16], but because
there is a gap in time between infection and viral clearance,
morbidity cannot be prevented completely. The mild mor-
bidity associated with CTL-based immune protection might
be regarded as a drawback, but initial rounds of replication
and the subsequent production of all viral antigens are
essential for building stronger and more cross-protective
adaptive immunity, as suggested by the data of Kreijtz et al.
[30].
CTLs responses in small animal models are often
analyzed in the spleen, one of the sites where antigen
presentation takes place. The few rounds of infection that
can occur in the presence of (cross)protective CTLs induced
by CTL-based vaccines probably enable the presentation of
antigen in secondary lymphoid organs and maybe even the
formation of inducible bronchus-associated lymphoid tissue
(iBALT) in response to influenza A virus infection. However,
influenza-mediated induction of iBALT has been shown to
be impaired after vaccination with an adjuvanted subunit
vaccine against a human A/H3N2 influenza virus, which
induces an antibody response that is thought to neutralize
the challenge virus [31]. It is important to appreciate the
contribution to the adaptive immune response of iBALT
formed in response to influenza A virus infection. This
iBALT has been observed in both mice and humans after
disease-related circumstances [32]. Distinct B-cell follicles
and T-cell areas as well as clearly defined germinal centers
have been described in iBALT [33], and DCs are crucial for its
organization and maintenance [34]. The adaptive response
resulting from iBALT formation is protective in mice and can
help contain the pulmonary infection even in the absence
of peripheral lymphoid organs [33]. The iBALT contributes
to the adaptive humoral immune response during influenza
infection and it will be interesting to investigate whether
the presence of protective influenza-specific T-cell precursors
raised by vaccination can influence the composition, kinetics
of formation, or role of iBALT. Deep pulmonary delivery of
vaccines is of special interest here, as this technique allows the
induction of antigen-specific cellular and antibody-mediated
immunity, the latter at both the systemic and mucosal levels
[35].
The few replication cycles allowed by the delayed pro-
tective mechanism of vaccine-induced CTLs may well allow
the induction of CTLs and helper T- (Th) cells targeting
antigens other than those included in the vaccine. Such
responses can further promote heterosubtypic protection as
discussed above. Bystander help from Th cells may consist
of more than production of cytokines to promote antibody
formation and isotype class switching. CD4+ T-cells have also
been reported to have perforin-dependent cytolytic eﬀector
functions that synergize with their bystander functions for
B cells after influenza infection [20]. On the other hand,
CTLs are thought to kill infected cells after recognition of
MHC-I-bound foreign peptides by delivering granzymes in
a perforin-dependent way or by induction of apoptosis in
the target cell by the Fas-pathway [36, 37]. The main task of
CTLs is believed to be the rapid reduction of the viral titers
in the lung by clearing infected cells [38]. Once the infection
is contained by elimination of infected cells, antibodies
that have been raised in the mean time can neutralize the
remaining viruses. Moreover, new evidence suggests that
CD8+ T- cells might also provide bystander help. Like
CD4+ helper T-cells, CD8+ T-cells are now classified into
Tc1, Tc2, and Tc17 cells, according to the cytokines they
produce [39–41]. As type 1 immune responses are needed
to fight intracellular infections, CTL vaccines should ideally
raise Tc1 instead of Tc2 CD8+ T cells. However, Oran and
Robinson [42] showed that the induction of a Th2/Tc2
response against the influenza NP did allow the induction
of a type 1 immune response at the site of infection.
Paradoxically, CD8+ T-cells are the main source of the anti-
inflammatory cytokine IL-10 in the lungs of mice infected
with influenza A virus [43]. In this model, IL-10 mitigates
the pathological eﬀects that are associated with excessive
CTL activity. However, this mitigation by IL-10 has to be
carefully balanced because IL-10 produced by CD8+ T cells
also suppresses a protective Th17 response in the lung
upon influenza infection. Naive IL-10 deficient mice control
influenza A virus infection much better than wild type mice
[44].
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4. CTL Vaccine Design
Like all other vaccines, an ideal CTL vaccine should be easy
to administer, eﬀective, and safe. Vaccine eﬃcacy means
that the vaccine oﬀers significant clinical protection against
infection by the corresponding pathogen. A vaccine strategy
that relies on CTL eﬀector mechanisms should induce
presentation of pathogen-derived epitopes to the immune
system and result in the formation of a pool of CTLs with
an eﬀector phenotype that can retract into long-lasting
memory. A prerequisite for eﬃcient MHC-I-presentation
of pathogen-derived peptides is that the antigen should
either be produced intracellularly or be cross-presented after
uptake. The former, far more eﬃcient mechanism can be
an achieved for example by use of an attenuated influenza
strain, a heterologous viral vector expressing influenza virus
antigens, or by gene vaccination.
Endosomal escape mechanisms have been shown to be
eﬀective in promoting cross-presentation of extracellularly
administered antigens derived from tumors or pathogens.
Cross-presentation of extracellular antigens can be enhanced
by diﬀerent means. One approach is to associate them with
heat shock proteins [45, 46] or to use cross-presentation
promoting systems based on lysteriolysin of L. monocytogenes
[47, 48]. Another approach involves encapsulation of the
antigen in biodegradable particles that can be taken up by
DCs [49, 50]. Certain adjuvants can also help promoting
cross-presentation [51].
Targeting conserved and immunodominant epitopes
with CTL vaccines could oﬀer protection during multiple
influenza seasons and potentially against pandemic virus
outbreaks. This is an attractive alternative for currently
licensed influenza vaccines. But for the CTL approach to
work, influenza antigen-specific CTLs should persist in
suﬃcient numbers for a long time, at least until a booster
signal is provided either by vaccination or by natural
exposure to influenza virus. Help from CD4+ T-cells and
a favorable cytokine environment are important during the
retraction of CTLs into memory and for maintenance of
these memory CTLs [52, 53]. By contrast, maintenance
of CD8+ T-cell memory does not require persistence of
antigen [54, 55]. Typically, memory CD8+ T cells are
subdivided, according to the expression level of the homing
receptors CCR7 and CD62L, in central memory T-cells
(Tcm, CCR7high CD62Lhigh) and eﬀector memory T-cells
(Tem, CCR7low CD62low). Tcm cells circulate in the blood
and among secondary lymphoid organs, whereas Tem cells
are found in peripheral tissue such as the lung as well as
in the blood and spleen [56, 57]. Tem cells are cytotoxic
and act rapidly to defend against infection, but they do not
proliferate. On the other hand, Tcm cells are responsible
for clonal expansion of antigen-specific CD8+ T-cells, which
may result in the formation of new eﬀector T-cells. However,
an infection might not be contained before exhaustion of the
residing pool of cytotoxic T-cells (consisting of preexisting
Tem or CTLs recruited from the Tcm pool to the site
of infection). In such cases, subsequent rounds of viral
replication can take place. To avoid this situation, it is crucial
to prime Tem in the lungs in order to contain an influenza
virus challenge in the early stages of infection. This is a
challenge that still hampers the development of eﬀective
CTL-based influenza vaccines.
When considering the safety of vaccines intended for
humans, it is not only the direct side eﬀects of vaccine
administration that should be evaluated. Some vaccines are
considered intrinsically safe because they do not replicate
or result in de novo synthesis of the microbial antigen.
These include peptide- or protein-based vaccines that rely
on cross-priming for the activation of CTLs, such as virion
like particles (VLPs), virosomes, ISCOMs [7, 58], inac-
tivated viruses, or adjuvanted subunit vaccines. However,
the situation is diﬀerent when using attenuated pathogens
or genetic vaccines. Live vaccines, for example, must have
limited replication competence, be genetically stable, and not
prone to gene swapping, and their use should be avoided in
immuno-compromised individuals. The modified Vaccinia
Virus Ankara (MVA) induces a potent humoral and cellular
immune answer and has been shown to be very safe for use
in humans, making it a good platform for the development
of influenza vaccines (reviewed in [59]). MVA can replicate
in human cells but it cannot produce mature MVA-particles
because its structural proteins cannot be proteolytically
processed in human cells [60].
Cold-adapted influenza viruses are another example of
safe live vaccines. Their replication is restricted to the upper
airways, and their infection is generally asymptomatic yet
suﬃcient to induce a protective immune response. The issue
of safety takes on a diﬀerent dimension when considering
vaccination with an expression plasmid [61], namely, the
possibility that the plasmid DNA or part of it might integrate
in the DNA of the host cells. The possibility of disrupting
tumor suppressor genes or activating oncogenes as a result
of such integrations remains a major concern. In addition,
it is possible that long-term expression of the antigen at
low levels might promote tolerance to the antigen. Finally,
the risk of raising anti-DNA antibodies, which are present
in patients with certain types of auto-immune disease, is
another concern [62–66].
There are several infectious diseases for which CTL-
dependent pathogen control does more harm than benefit
following a subsequent infection [67–69]. Exacerbation of
disease by virus-specific CTLs has indeed been shown in
the influenza mouse model [70, 71]. Given the potentially
destructive nature of CTLs and by extension several other cell
types of the immune system, it is not surprising that several
feedback mechanisms control inflammation in general and
contain excessive CD8+ T-cell activity specifically during
infection [43, 72, 73]. Moﬀat et al. [74] investigated the
expression levels of granzyme A (grzA) and B (grzB) in CTLs
with diﬀerent influenza A virus antigen specificity during
an influenza A virus infection. They concluded that CTLs
specific for diﬀerent influenza epitopes showed a hierarchy of
grzA expression, and that this hierarchy inversely correlated
with the magnitude of the CTL response. In the discussion
they point to the study of Metkar et al. [75], who showed
that both human and mouse grzA can stimulate monocytic
cells to produce proinflammatory cytokines, a phenomenon
that can worsen the outcome of an influenza infection
Journal of Biomedicine and Biotechnology 5
[76]. Obviously, a safe CTL-based vaccine for influenza
should be able to induce a protective CTL response without
exacerbating the disease.
It is important to consider that most CTL epitopes of
human influenza viruses that were identified until recently
were highly conserved. However, to evade immune surveil-
lance by CTLs, viruses have developed diﬀerent mechanisms
to prevent recognition by specific CTL. One of these
mechanisms that appears to drive influenza A virus antigenic
variation is the accumulation of mutations in or adjacent
to CTL epitopes, which can aﬀect peptide processing and
presentation, binding to MHC class I molecules, and/or
recognition by specific T-cells [77, 78].
5. Novel Vaccine Design: What Can Databases
and Prediction Algorithms Do for Us?
Our understanding of T-cell biology and presentation
of antigens by the immune system has grown consid-
erably over the last decades. The exponential expansion
of data available forces scientists to rely on bioinfor-
matics tools to extract relevant information about epi-
topes of interest from several databases. To do this eﬃ-
ciently and accurately, these databases should be properly
curated and transparent. Several general or pathogen-
specific databases containing immune-epitope related data
are available (reviewed in [79]). Databases often come
with computational tools for optimal use of the resource.
Worthy of mention is the recently redesigned Immune
Epitope Database and Analysis Resource (IEDB), which is
accessible at http://www.immuneepitope.org/ [80, 81]. This
database is curated according to well-defined guidelines,
allowing objective representation of immune epitope data
gathered by the scientific community, and integrates these
data with other knowledge resources [82–84]. In 2007,
IEDB was used to inventorize the existing knowledge on
influenza A epitopes [85]. That analysis provides a resource
for influenza researchers and illustrates the possibility of
identifying cross-reactive epitopes in diﬀerent influenza
strains, which might be of great value for the development
of HSI-inducing vaccines. More recently, the IEDB was used
experimentally to identify preexisting human CD4+ and
CD8+ T-cell immunity against the pandemic A/H1N1/2009
influenza virus of swine origin [86]. The availability of
immune-epitope related databases combined with a growing
understanding of the events involved in antigen processing
and presentation allowed the development of computational
methods for prediction of novel T-cell epitopes for diﬀerent
species taking into consideration specific MHC alleles.
The faster identification of immune-related data by use of
the prediction tools allows the databases to be populated
even more quickly. Many of these prediction tools are
available through the internet (reviewed in [79, 87, 88])
and some of them are hosted by the IEDB. Guidelines and
specifications are provided for the design and validation
of computational models used for T-cell epitope predic-
tion as well as assistance in selecting the most suitable
prediction tools and selection criteria [89–91]. Especially
for MHC-I-binding peptides, these tools have reached a
level of accuracy that justifies their use in fundamental
research and during the initial phases of vaccine devel-
opment; they can substantially reduce the cost and work-
load associated with wet-lab validation of novel epitopes
[92–94].
Similar to the study of Greenbaum et al. mentioned
above [86], De Groot et al. [95] used immunoinformatics
to compare T-cell epitopes contained within the pandemic
A/H1N1/2009 influenza virus with those in the conventional
vaccine used during the 2008-2009 flu season. Prediction of
T-cell epitopes based on peptide-MHC-I binding is often
successful [93], but a combination of binding aﬃnities with
predicted proteasome-mediated cleavage sites and estimated
TAP aﬃnity can further improve the accuracy of class I T-
cell epitope prediction algorithms [96]. Combining multiple
methods for predicting each individual step in the immune
presentation process might even improve the predictive
power [97]. On the other hand, including TAP aﬃnity
will eliminate TAP-independent peptides, which translates
into a chance of excluding vaccine candidates from further
investigation [91].
Vaccine design is also expected to benefit increasingly
from immunomics, the study of immunological interac-
tions between host and pathogen or host and antigen,
including host-vaccine interactions. A combination of clas-
sical immunology and immunoinformatic tools is used
for collecting, analyzing, and managing the huge amount
of immune-related data currently available. Ultimately,
a solid understanding of complex immune interactions
might allow the modeling of complex host-pathogen or
host-antigen interactions, thereby enabling us to study
and predict more correctly the outcome of a vaccination
[98, 99].
6. Vaccine Efficacy and Correlates of Protection
The measurement of vaccine antigen-specific humoral and
cellular immune responses induced by vaccination can help
to estimate the eﬃcacy of a given vaccine. However, of even
more importance for vaccine development is the degree to
which these immune responses correlate with protection
upon challenge. Since decades the serum antibody titer
that inhibits hemagglutination (HAI) of red blood cells
by influenza virions is the gold standard for determining
the correlate of protection for the licensed influenza vac-
cines. According to the guidelines of the Food and Drug
Administration, the eﬀectiveness of an HA-based vaccine,
including DNA vaccines expressing the HA gene, is measured
as (1) the geometric mean HAI titer, and (2) the rate of
seroconversion defined as the proportion of subjects with
at least a fourfold rise of the HAI titer after vaccination
(http://www.fda.gov/BiologicsBloodVaccines/Guidance
ComplianceRegulatoryInformation/Guidances/Vaccines/
ucm074794.htm). These guidelines also take into consid-
eration the pediatric population and the steadily growing
group of adults over 65 years of age. The latter group
has an increased risk of influenza-related disease and is
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considered a priority group for seasonal influenza vac-
cination. However, the antibody response to vaccination
declines with age, which stresses the need for better influenza
vaccines. However, it is not clear whether the induced HAI
titer in a given test population provides equal confidence
of protection against influenza disease in children, adults,
and the elderly. McElhaney et al. compared serum HAI
titers and ex vivo cellular immune responses to influenza
vaccination in young adults and elderly adults (≥60 years)
[100, 101]. They concluded that T-cell responses are better
correlates of protection in the elderly. Nevertheless, as
already mentioned in the introduction, antibodies against
nucleoprotein are protective during influenza infection in
a mouse model [102]. The mechanism by which these
antibodies protect will almost certainly not be neutral-
ization. Depending on the vaccine architecture and vac-
cination protocol, it is reasonable to expect that vaccina-
tion with CTL-vaccines targeting neutralization-insensitive
internal proteins will also induce an antibody response,
and it is therefore worth investigating whether the unin-
tentionally induced antibody response also correlates with
protection.
In contrast to the readouts for humoral responses upon
vaccination, it is more diﬃcult to apply practical and
reproducible readouts that can be used as correlates of
protection for cellular immunity. The importance of CTLs
as correlates of protection in anti-influenza immunity has
already been addressed elsewhere in depth [103, 104]. We
will limit the discussion here to some indications that
CTLs correlate with protection during influenza infection
in humans and focus on some techniques for functional
analysis of T-cell responses.
There is limited evidence for CTL-mediated clinical
protection during influenza infection in humans. The exper-
imental infection study conducted by McMichael et al. [105]
is the only study that directly shows a correlation between
influenza-specific CTL activity and protection by measuring
virus shedding. Epidemiological studies support these data
but they rather document HSI without analysis of correlating
specific CTLs in humans [106, 107]. Ex vivo evidence for
HSI due to CTLs in humans is provided by the observation
of cross-reactive CTLs in PBMCs that recognize peptides
derived from avian and swine influenza [108–110]. Finally,
the variation in CTL epitopes observed in H3N2 viruses that
have been circulating for 10 years suggests that these epitopes
are under selective pressure, which is an indirect indication
for the contribution of human CTLs to the antiviral activity
directed against the major T-cell antigen of influenza A
viruses [111].
7. Techniques for Analysis of T-Cell Responses
Estimation of T-cell activation ex vivo is relatively straight-
forward in a well-equipped immunology laboratory. Dif-
ferent assays are available, but they require more complex
infrastructure than the HAI assay. For example, cytokine
profiles are often analyzed in lung immune cells obtained
from mouse bronchioalveolar lavage (BAL), peripheral blood
mononuclear cells (PBMCs), or splenocytes after restim-
ulation with antigen. Quantification of cytokines secreted
in the medium by ELISA or by flow cytometry- (FC-)
based techniques is often combined with techniques that
allow exact counts of the number of cytokine-secreting cells,
such as ELISPOT and intracellular staining of the cytokine
(ICS) by flow cytometric analysis. The latter technique
allows the functional characterization (phenotype, activation
state, peptide restriction) of the cytokine producing cells
by costaining of surface markers and tetramer stainings for
epitope-specificity. The technical advancements made over
the recent years have elevated the flow cytometer (FC) to
an almost indispensable research tool for immunology and
by extension for vaccine development. The most important
advancements in this respect are its suitability for high-
throughput screening and its quantitative output, which
allows rigorous and statistically sound testing of hypotheses.
Moreover, FC allows simultaneous multiparametric analysis
of both humoral and cellular immune responses (reviewed
in [112]).
CTLs contribute to protection by eliminating infected
cells, which should reduce virus titers in the lung in the case
of an influenza virus infection. Trying to find a correlation
between killer capacities of CTLs and protection might
therefore be relevant. Using human PBMCs with an in
house-developed assay based on a substrate of grzB showed
that grzB correlates with protection in the elderly, where
protection was defined as absence of labarotory-diagnosed
influenza virus [101, 113, 114]. The release of GrzB by killer
cells into target cells can be detected by using fluorogenic
probes based on the DNA-dependent protein kinase catalytic
subunit, which is the substrate for grzB [115]. For many
years, CTL activity has been estimated by a technique
described more than forty years ago [116]. This technique
measures the release of 51Cr from radioactively labeled target
cells when they are killed by eﬀector cells. Such release
assays, however, do not have single cell resolution and as
such do not allow any further characterization of the target
and/or eﬀector cells. Several techniques that can be used to
estimate the killing activity by CTLs have been developed,
some of which were borrowed from research in the cell
death field. Staining of cleaved caspase 3 or using fluorogenic
protease substrates can reveal induction of CTL-mediated
apoptosis in the target cells [115, 117, 118]. Other FC assays,
such as the FL-CTL and FATT-CTL, quantify CTL activity
by monitoring the elimination of fluorescently labeled,
transfected target cells after coincubation with eﬀector cells
[119, 120].
All the techniques mentioned above rely on ex vivo
measurements of killing activity, sometimes after in vitro
restimulation. Therefore the deprivation of killer cells from
factors only available in vivo might bias the outcome and
interpretation of a killing assay. A solution for this potential
pitfall is the development of an in vivo killing assay in
which CFSE-labeled target cells are adoptively transferred
into mice and killing is followed using FC [121]. However,
this limits the technique to investigations in experimental
animal models.
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Figure 1: Immunomics comprises the study of immunological processes, thereby integrating new technologies and immunoinformatics
tools from which the development of CTL vaccines can benefit. Immunoinformatics allows to collect, analyze, and manage data from
research or the clinic into databases. This allows in return to formulate new research hypotheses or the prediction of new vaccine candidates.
Promising epitopes are validated as vaccines in experimental set-ups or clinical trials. Hereby vaccines can be used as tools to address
fundamental research questions, and immunological analysis can provide means to estimate vaccine eﬃcacy or to determine correlates of
protection. The many feed back loops in the system allow optimization of the development process and might ultimately result in a CTL-
based vaccine that can induce heterosubtypic immunity against influenza.
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The need for influenza vaccines that induce HSI is not met
by the current seasonal or pandemic (e.g., H1N1v-targeted)
influenza vaccines, which rely on humoral immunity against
HA and NA. Both the humoral and cellular branches of the
immune system are involved in adaptive HSI (reviewed in
[122]). The induction of HSI has been studied in animal
models, but clearly defined general correlates of protection
for HSI in humans are not available. The presence of virus-
specific CTLs induced during a previous infection correlates
with protection upon challenge with a heterologous virus
in mice [30] and in humans [105]. The presence of HSI
in a population might mitigate the clinical outcome of
a newly emerging epidemic or pandemic influenza strain.
Interestingly, it was recently shown in mice that eﬀective
vaccination with inactivated virus inducing HAI against
an A/H3N2 strain prevented the subsequent induction of
HSI against an avian A/H5N1 influenza strain, which was
eﬃciently mounted by prior infection of naı¨ve animals with
a human A/H3N2 strain [31]. The authors of this study state
that these findings might have implications for vaccination
strategies for children, who, early in life, are immunogeni-
cally naı¨ve for influenza. Therefore, the question was raised
whether we should first vaccinate this population with live-
attenuated vaccines [123] or only start vaccination after a
first natural infection, in which case a strong, cross-specific
cellular immune response would be induced in response
to the replicating virus. The vaccination of young children
against influenza with current seasonal vaccines and the
possibly reduced eﬃcacy of induction of cellular immunity
has been debated for several years [124–127]. HSI induced
by CTL-based influenza vaccines is conceivable and might
have major advantages over licensed influenza vaccines for
this particular age group. CTL vaccines might make the
aforementioned discussion obsolete because induction of
CTLs, for example by DNA vaccination against the conserved
internal genes, can take place in the presence of neutralizing
antibodies directed against the surface molecules HA and
NA induced by vaccination with classical vaccines. Also the
elderly might benefit from CTL vaccines, as vaccine-induced
T-cell responses are better correlates of protection in this age
group [100].
Immunoinformatic tools help us capturing, analyzing,
and managing the massive amounts of immune-related
data that has been gathered from experiments over the
years and that continues to be generated every day. Large
curated databases come with bioinformatics tools to opti-
mize exploitation of the stored data and allow development
of improved prediction tools for new vaccine candidates.
Prediction tools can significantly speed up the process of
discovering new epitopes by downscaling costly and labor-
intensive wet-lab experiments. The multidisciplinary field of
immunomics will provide a platform for strategic vaccine
research [128] and will aid in defining good correlates of
protection for cellular immunity (see Figure 1). Recent
research suggests that T- cell responses following infection
or immunization are directed against a broader spectrum
of epitopes than previously assumed [129]. The broader
immune recognition does not conflict with the idea of
immunodominance, as dominant epitopes still account for
the major part of the CTL-response. The use of immunomic
tools also helps to reveal subdominant epitopes. Including a
selection of these epitopes in a CTL vaccine might improve
the vaccine’s protective capacity as well as induce HSI. As
several cell types are involved in the activation of CTLs, the
concept of CTL vaccines might be broadened to vaccines that
also target other cell types. Induction of bystander help from
CD4+ T cells might be as important for CTL activation as the
binding of the epitope to MHC molecules for presentation
purposes.
Some novel approaches for measuring T-cell activation
are based on technologies that have not been widely
integrated in immunology-related research. But these tech-
nologies might gain importance in future vaccine research
and in the search for immune correlates of protection. For
example, the nanoscale solid-state complementary metal-
oxide-semiconductor technology can measure T-cell activa-
tion in an antigen specific way within seconds, and it is
therefore suitable for studying kinetics of T-cell activation
[130]. Peptide-MHC microarrays, which were developed
some years ago, allow fast and simultaneous activation, char-
acterization, isolation, and identification of peptide-specific
T-cell populations [131]. Newly emerging applications, such
as those mentioned here, might find their way to large-scale
epitope screens, and together with computational tools speed
up vaccine discovery.
The challenge for vaccine research and development
in the future is to integrate our current knowledge
on immunology and T-cell biology in particular with
immunoinformatic tools and immunotechnology into a
higher-order system. Such a system will enable us to rapidly
validate novel epitopes, which will provide us with the means
to develop safe and eﬃcient vaccines, such as the HSI-
inducing CTL vaccines discussed in this review.
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